Despite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma.
Crystal Ritchey, PhD
Articles by Crystal Ritchey, PhD
Latest Updated Articles
Risk-Based Treatment of Hodgkin Lymphoma in the Era of Novel TherapiesSeptember 9th 2023